Article

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools

2021-09-24

Abstract excerpt

Therapeutic proteins, including monoclonal antibodies, are typically manufactured using clonally-derived, stable host cell lines, since consistent and predictable cell culture performance is highly desirable. However, selecting and preparing banks of stable clones takes considerable time, which inevitably extends overall development timelines for new therapeutics by delaying the start of subsequent activities, suc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a9f47818-a875-5518-b1c0-6d4efe7ba18d
DOI: 10.22541/au.163251349.96835693/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsDOI 10.22541/au.163251349.96835693/v1Read

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO poolsSemantic proximity Read

Utilizing non-clonal CHO cell derived materials for preclinical studies of complex moleculesSemantic proximity Read

Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon systemSemantic proximity Read

Shortening the Biologics Clinical Timeline with a Novel Method for Generating Stable, High Producing Cell Pools and ClonesSemantic proximity Read

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-CloningSemantic proximity Read

Recombinant antibody-producing stable CHOK1 pool stability studySemantic proximity Read

Reshaping Cell Line Development and CMC Strategy for Fast Responses to Pandemic OutbreakSemantic proximity Read

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144Semantic proximity Read

A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigensSemantic proximity Read

When will we have a clone? An industry perspective on the typical CLD timelineSemantic proximity Read

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read